Supply Chain Intelligence

Vor Biopharma Inc. Supply Chain

VOR supply chain intelligence for Vor Biopharma Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

VOR ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

18Suppliers
11Customers
3Debt Items
20Related Chains

Vor Biopharma Inc. Suppliers

TickerNameConfidenceEvidence
REMEGEN REMEGEN 92% In June 2025, we entered into a license agreement with RemeGen (the “Telitacicept License Agreement”) granting us an exclusive (even as to RemeGen) license under RemeGen’s patents and know-how to exp…
TELITACICEPT-LICENSE-AGREEMENT TELITACICEPT-LICENSE-AGREEMENT 90% The Company incurred $ 0.2 million in transaction costs related to the Telitacicept License Agreement during the year ended December 31, 2025.
THE-TRUSTEES-OF-COLUMBIA-UNIVERSITY-IN-THE-CITY- THE-TRUSTEES-OF-COLUMBIA-UNIVERSITY-IN-THE-CITY- 90% including the exclusive license agreement with The Trustees of Columbia University in the City of New York
U-S-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES U-S-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES 90% patent license agreement with the U.S. Department of Health and Human Services, as represented by National Cancer Institute of the National Institutes of Health
A Agilent Technologies, Inc. 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
A Agilent Technologies, Inc. 72% Reciprocal relationship from A graph: Reciprocal relationship from VOR graph: Reciprocal relationship from A graph: Reciprocal relationship from VOR graph: Reciprocal relationship from A graph: Recip…
JAZZ Jazz Pharmaceuticals plc 72% Reciprocal relationship from JAZZ graph: Reciprocal relationship from VOR graph: Vanflyta (quizartinib), Jazz Pharmaceuticals plc’s Vyxeos (daunorubicin and cytarabine), Novartis International AG’s R…
JAZZ Jazz Pharmaceuticals plc 72% Vanflyta (quizartinib), Jazz Pharmaceuticals plc’s Vyxeos (daunorubicin and cytarabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylotarg (gemtuzumab ozogamicin) and Daurismo …
MYGN Myriad Genetics, Inc. 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need …
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need…
NVSEF Novartis AG 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
RIGL Rigel Pharmaceuticals, Inc. 72% Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR graph: arabine), Novartis International AG’s…
RIGL Rigel Pharmaceuticals, Inc. 72% arabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylotarg (gemtuzumab ozogamicin) and Daurismo (glasdegib), Rigel Pharmaceuticals, Inc.’s Rezlidhia (olutasidenib), and Syndax…
SGMO Sangamo Therapeutics, Inc. 72% Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such…
SGMO Sangamo Therapeutics, Inc. 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
SNYNF Sanofi 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with su…

Vor Biopharma Inc. Customers

TickerNameConfidenceEvidence
TCGX TCGX 90% The Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the 'Shares') of the Company's common stock, at a price per Share of $14.05, for gross…
A Agilent Technologies, Inc. 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
A Agilent Technologies, Inc. 72% Reciprocal relationship from A graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to …
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need …
MYGN Myriad Genetics, Inc. 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from NVSEF …
NVSEF Novartis AG 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
SGMO Sangamo Therapeutics, Inc. 72% Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SGMO gra…
SGMO Sangamo Therapeutics, Inc. 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
SNYNF Sanofi 72% lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our …
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need…

Vor Biopharma Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
VOR-DEBT-13408 Warrants outstanding: 334358000 90% xbrl warrant detail from xbrl 2025-12-31.
VOR-DEBT-13409 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
VOR-DEBT Debt stack $2.9M 90% Market cache reports total debt of $2.9M.

Vor Biopharma Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vor Biopharma Inc..

Vor Biopharma Inc. Ownership

HolderNameConfidenceEvidence
VOR-OWNER-TCG-CROSSOVER-MANAGEMENT-LLC TCG Crossover Management, LLC 90% 13F overlay lists TCG Crossover Management, LLC as top holder; 80 tracked holders.

Vor Biopharma Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CYTK Cytokinetics, Incorporated 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
BNBX BNB Plus Corp. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
BLLN BillionToOne, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CLYM Climb Bio, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
View VOR supply chain intel →

Explore the full interactive supply chain map for Vor Biopharma Inc..

Open VOR supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map